Personalis (NASDAQ:PSNL) Downgraded by Needham & Company LLC to “Hold”

Needham & Company LLC downgraded shares of Personalis (NASDAQ:PSNL) from a buy rating to a hold rating in a research report released on Monday morning, Marketbeat.com reports.

PSNL has been the topic of several other reports. Morgan Stanley raised their price objective on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. BTIG Research reduced their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.25.

Personalis Price Performance

NASDAQ PSNL opened at $13.34 on Monday. The business has a fifty day moving average price of $11.09 and a two-hundred day moving average price of $8.94. The stock has a market capitalization of $1.40 billion, a PE ratio of -13.08 and a beta of 2.24. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $16.39.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. As a group, sell-side analysts expect that Personalis will post -1.07 earnings per share for the current year.

Insiders Place Their Bets

In other Personalis news, CFO Aaron Tachibana sold 4,982 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares in the company, valued at $3,558,668.88. The trade was a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock worth $5,599,929 in the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PSNL. Caitong International Asset Management Co. Ltd grew its stake in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the last quarter. Deutsche Bank AG raised its position in Personalis by 4.5% during the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares during the last quarter. Royal Bank of Canada lifted its holdings in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares during the period. Howland Capital Management LLC lifted its holdings in Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after buying an additional 2,500 shares during the period. Finally, Intech Investment Management LLC grew its position in shares of Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after buying an additional 3,851 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Trending Headlines about Personalis

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Tempus AI’s acquisition gives Personalis shareholders a defined exit price of $16.25 per share, which is above the current trading level and reflects a premium to prior prices. Article Title
• Positive Sentiment: The deal could expand Personalis’ reach through Tempus’ AI-enabled precision oncology platform, supporting longer-term strategic value for the business. Article Title
• Neutral Sentiment: BTIG raised its price target on Personalis to $16.25 and kept a buy rating, signaling analyst confidence in the valuation implied by the acquisition. Article Title
• Negative Sentiment: Multiple shareholder-rights law firms have announced investigations into whether the Tempus deal delivers a fair price, raising the possibility of legal challenges or added transaction uncertainty. Article Title
• Negative Sentiment: Needham downgraded Personalis from buy to hold, adding to a more cautious tone around the stock despite the takeover announcement. Article Title

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.